Mads Israelsen
LightNews LightNews
banner
israelsenm.bsky.social
Mads Israelsen
@israelsenm.bsky.social
190 followers 110 following 10 posts
MD PhD. Hepatology researcher. Odense Liver Research Center. EASL YI Task Force.
Posts Replies Media Videos
Reposted by Mads Israelsen
lancetgastrohep.bsky.social
New research - Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study

www.thelancet.com/journals/lan...

#LiverSky #MedSky @aleksanderkrag.bsky.social @israelsenm.bsky.social
September 11, 2025 at 7:14 AM
israelsenm.bsky.social
How should we use PEth in SLD care? 🩸🍺

Our study in @lancetgastrohep.bsky.social (n≈3,000) shows:
🔍 39% of MASLD → MetALD/ALD with PEth
⨻ Triangulating self-report + AUDIT-C + PEth = better classification
⚖️ But 40% get no added value → use selectively

www.sciencedirect.com/science/arti...
Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study
Phosphatidylethanol is a direct biomarker of alcohol consumption within the past 1–4 weeks, making it a potential tool in the subclassification of pat…
www.sciencedirect.com
September 11, 2025 at 7:05 AM
Reposted by Mads Israelsen
lancetgastrohep.bsky.social
New Review - Screening for advanced steatotic liver disease

www.thelancet.com/journals/lan...

#LiverSky #MedSky @aleksanderkrag.bsky.social
Screening for advanced steatotic liver disease
Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early detection of advanced liver disease through screening presents an opportunity...
www.thelancet.com
July 16, 2025 at 6:09 AM
Reposted by Mads Israelsen
jhep-reports.bsky.social
🎉Our new Impact Factor is 7.5!

We are firmly among the top journals in hepatology👏

Thank you to our authors, reviewers & readers!🙏

#LiverSky
@easlnews.bsky.social
June 24, 2025 at 2:49 PM
Reposted by Mads Israelsen
lancetgastrohep.bsky.social
New Editorial — Alcohol and health: time for Europe to sober up

www.thelancet.com/journals/lan...

#alcohol #liversky #medsky
June 6, 2025 at 12:53 PM
Reposted by Mads Israelsen
jhepatology.bsky.social
📢Our new Impact Factor is 33.0🎉

🥇Ranking number 1 in the Hepatology field🥇

👏Thanks to the Editorial Team, untiring peer reviewers & very innovative authors❕

#LiverSky
@easlnews.bsky.social
June 18, 2025 at 7:57 AM
Reposted by Mads Israelsen
a-tango.bsky.social
✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement.

🗓️ What a fun #workshop at #EASLCongress 2025
May 12, 2025 at 6:35 AM
Reposted by Mads Israelsen
microb-predict.bsky.social
🧪 Mads Israelsen (Odense Universitetshospital – Svendborg Sygehus) leads together with Alberto Zanetto the YI #Workshop on How to prepare a #Clinical #Practice #Guideline in Hepatology, offering valuable insights for young investigators.

📅 Presented at the #EASLCongress | #EASL2025
May 10, 2025 at 9:17 AM
Reposted by Mads Israelsen
microb-predict.bsky.social
One last time #LIVE from the #EASLStudio: Tot Ziens Amsterdam, Hola Barcelona! 👋

As #EASL2025 draws to a close, Debbie Shawcross and Aleksander Krag reflect on the highlights from Amsterdam and set the stage for #EASL2026 in Barcelona.

Thank you for an inspiring #EASLCongress - see you next year!
May 10, 2025 at 10:01 AM
Reposted by Mads Israelsen
microb-predict.bsky.social
🤩 Full house at General Session 1 today 🥳

Abstract Session “General #Hepatology”, chaired by Aleksander Krag from Odense University Hospital in Denmark 🇩🇰, featuring a broad range of cutting-edge #LiverResearch 🔬.

📅 Presented at #EASLCongress | #EASL2025

🕥 10:30 – 12:30 h

@easlnews.bsky.social
May 8, 2025 at 9:40 AM
Reposted by Mads Israelsen
microb-predict.bsky.social
📚 Learning from the best at the EASL Congress: Maja Thiele (OUH) discusses Alcohol-related liver disease as part of The JHEP Reports Symposium: Keys to get your manuscript accepted. 💡
#EASL2025
May 8, 2025 at 3:55 PM
Reposted by Mads Israelsen
microb-predict.bsky.social
🐭 Blockage of microfibrillar-associated protein 4 (MFAP4) decreases liver fibrosis in two murine models of steatotic liver disease

#POSTER THU-058-YI by Maximilian Brol (UM) presents preclinical data showing that blocking MFAP4 reduces #liver #fibrosis in two murine models.

#EASL2025
May 8, 2025 at 2:05 PM
Reposted by Mads Israelsen
nejm.org
In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM

#MedSky #EndoSky #GastroSky
The figure shows the percentage of patients with fibrosis stage 2 or 3 who had resolution of steatohepatitis with no worsening of liver fibrosis (Panel A) and reduction in liver fibrosis with no worsening of steatohepatitis (Panel B) after 72 weeks, with the estimated difference expressed in percentage points.
April 30, 2025 at 9:10 PM
Reposted by Mads Israelsen
liverepi.bsky.social
🚨New paper from us in Journal of Hepatology - Using PEth values on >50,000 persons to predict outcomes. www.sciencedirect.com/science/arti...
Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes
Phosphatidylethanol (PEth) is an ethanol metabolite used as a specific biomarker for recent alcohol consumption. We aimed to determine the proportion …
www.sciencedirect.com
April 13, 2025 at 8:58 AM
Reposted by Mads Israelsen
natrevgastrohep.nature.com
APRIL ISSUE | Our Featured PERSPECTIVE is on "The steatotic liver disease burden paradox: unravelling the key role of alcohol"

www.nature.com/articles/s41...

#Liversky
Fig. 4: The bidirectional linking of factors that predispose to steatotic liver disease.
March 31, 2025 at 9:16 AM
Reposted by Mads Israelsen
israelsenm.bsky.social
@aga-cgh.bsky.social
@majathiele.bsky.social
@aleksanderkrag.bsky.social

#Thorhauge
April 8, 2025 at 6:13 AM
israelsenm.bsky.social
Our newdata show 38% of individuals with SLD are reclassified over 2 years ‼️

Over 60% with MetALD/ALD and 38% with MASLD change subclass.

This highlights that alcohol use and metabolic risk need regular reassessment, incl. for clinical trial eligibility 🧐

Link: www.cghjournal.org/article/S154...
Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments
Steatotic liver disease (SLD) includes the subclasses metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic and alcohol-related liver disease (MetALD) and alcohol-related liver d...
www.cghjournal.org
April 8, 2025 at 6:13 AM
Reposted by Mads Israelsen
natrevgastrohep.nature.com
#liversky #gastrosky #oncsky
natrevgastrohep.nature.com Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · Mar 31
Our APRIL ISSUE is live! Steatotic liver disease and alcohol, disorders of gut–brain interaction, coeliac disease, advanced chronic liver disease, and much more!

www.nature.com/nrgastro/vol...
Steatotic liver disease burden paradox, inspired by the Perspective on p281.
March 31, 2025 at 2:57 PM
israelsenm.bsky.social
MASLD vs MetALD/ALD is often reduced to ‘alcohol or not’.

But alcohol use is not binary—and SLD is a dynamic spectrum where alcohol plays a significant role across phenotypes.

Time to rethink the simplistic divide 🧐

@aleksanderkrag.bsky.social
@natrevgastrohep.bsky.social
April 1, 2025 at 9:20 AM
Reposted by Mads Israelsen
easlnews.bsky.social
Have you secured your spot for #EASLCongress 2025 on 7-10 May?

🌍Join us in Amsterdam or online to transform liver care worldwide! easlcongress.eu/2025-registr...
📜The deadline to submit your late-breaker abstract is TODAY, 17 March! easlcongress.eu/2025-abstrac...
March 17, 2025 at 8:51 AM
Reposted by Mads Israelsen
lancetgastrohep.bsky.social
New Review - Neurath, Artis, Becker - The intestinal barrier: a pivotal role in health, inflammation, and cancer

www.thelancet.com/journals/lan...

#GastroSky #MedSky
March 12, 2025 at 9:50 AM
Reposted by Mads Israelsen
ebtapper.bsky.social
AASLD is here

@aasldnews.bsky.social
@aasldfoundation.bsky.social

#liversky
ebtapper.bsky.social Elliot Tapper @ebtapper.bsky.social · Nov 15
We are on our second starter pack for GI / Hepatology
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR

#medsky #GIsky #LiverSky
March 9, 2025 at 4:52 PM
Reposted by Mads Israelsen
borklab.bsky.social
We're once again hosting the Human #Microbiome conference at @embl.org, organized by Ami Bhatt, Nicola Segata, Mani Arumugam and Peer Bork! We always have a great lineup of speakers, so register now and think about an abstract to submit (abstract submission deadline in June)
events.embl.org EMBL Events @events.embl.org · Feb 26
📣 Explore cutting-edge breakthroughs in microbiome research, from methodological innovations to integrative approaches and personalised therapeutics. Join #EESMicrobiome!🦠

📅 16 – 19 Sep 2025
📍 EMBL Heidelberg and Virtual
📥 Submit your abstract by 24 June

➡️ https://s.embl.org/ees25-08-bl
February 26, 2025 at 7:19 PM
Reposted by Mads Israelsen
jhepatology.bsky.social
Journal of Hepatology is now on Bluesky 🌤️

📢Check our January issue❗️

🎉Celebrating 40 years of discovery in #liverresearch🎉

🙏Thank you to our authors, editors, reviewers, & readers for supporting us on this incredible journey

Full issue here👉https://bit.ly/42en2Kp

#LiverSky
@easlnews.bsky.social
January 17, 2025 at 11:10 AM